CYTK - Cytokinetics to Host Virtual Investor & Analyst Day on October 19 2023 | Benzinga
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET. The event, entitled New Horizons in Hypercontractility, will feature presentations from senior leaders about the Company's cardiac myosin inhibition programs in hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), including new longer-term data from FOREST-HCM (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open-label extension clinical study of aficamten in patients with HCM, pre-clinical data for CK-4021586 (CK-586), a novel cardiac myosin inhibitor being developed for the potential treatment of patients with HFpEF, and an update on Cytokinetics' commercial readiness activities and corporate strategy.
A panel discussion on the current HCM disease landscape and the unmet need in this patient population will feature the following experts:
- Theodore Abraham, M.D., FACC, FASE, Meyer Friedman Distinguished Professor of Medicine, Division of Cardiology, University of California, San Francisco; Co-director, UCSF HCM Center of Excellence; Director, UCSF Adult Cardiac Echocardiography Laboratory
- Caroline Coats, Ph.D., Clinical Senior Lecturer, School of Cardiovascular & Metabolic Health, University of Glasgow
- Carolyn Ho, M.D., Associate Professor, Harvard Medical School, Medical Director of the Cardiovascular Genetics Center
In addition, a conversation with a person ...